Online citations, reference lists, and bibliographies.

Association Of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis

Chao Zeng, Maureen Dubreuil, Marc R. Larochelle, Na Lu, Jie Wei, Hyon K Choi, Guanghua Lei, Yuqing Zhang
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance An American Academy of Orthopaedic Surgeons guideline recommends tramadol for patients with knee osteoarthritis, and an American College of Rheumatology guideline conditionally recommends tramadol as first-line therapy for patients with knee osteoarthritis, along with nonsteroidal anti-inflammatory drugs. Objective To examine the association of tramadol prescription with all-cause mortality among patients with osteoarthritis. Design, Setting, and Participants Sequential, propensity score–matched cohort study at a general practice in the United Kingdom. Individuals aged at least 50 years with a diagnosis of osteoarthritis in the Health Improvement Network database from January 2000 to December 2015, with follow-up to December 2016. Exposures Initial prescription of tramadol (n = 44 451), naproxen (n = 12 397), diclofenac (n = 6512), celecoxib (n = 5674), etoricoxib (n = 2946), or codeine (n = 16 922). Main Outcomes and Measures All-cause mortality within 1 year after initial tramadol prescription, compared with 5 other pain relief medications. Results After propensity score matching, 88 902 patients were included (mean [SD] age, 70.1 [9.5] years; 61.2% were women). During the 1-year follow-up, 278 deaths (23.5/1000 person-years) occurred in the tramadol cohort and 164 (13.8/1000 person-years) occurred in the naproxen cohort (rate difference, 9.7 deaths/1000 person-years [95% CI, 6.3-13.2]; hazard ratio [HR], 1.71 [95% CI, 1.41-2.07]), and mortality was higher for tramadol compared with diclofenac (36.2/1000 vs 19.2/1000 person-years; HR, 1.88 [95% CI, 1.51-2.35]). Tramadol was also associated with a higher all-cause mortality rate compared with celecoxib (31.2/1000 vs 18.4/1000 person-years; HR, 1.70 [95% CI, 1.33-2.17]) and etoricoxib (25.7/1000 vs 12.8/1000 person-years; HR, 2.04 [95% CI, 1.37-3.03]). No statistically significant difference in all-cause mortality was observed between tramadol and codeine (32.2/1000 vs 34.6/1000 person-years; HR, 0.94 [95% CI, 0.83-1.05]). Conclusions and Relevance Among patients aged 50 years and older with osteoarthritis, initial prescription of tramadol was associated with a significantly higher rate of mortality over 1 year of follow-up compared with commonly prescribed nonsteroidal anti-inflammatory drugs, but not compared with codeine. However, these findings may be susceptible to confounding by indication, and further research is needed to determine if this association is causal.
This paper references
10.2307/3172772
Multiple imputation for nonresponse in surveys
Donald B. Rubin (1987)
10.1111/j.1365-2125.2007.03038.x
Perforated peptic ulcer and short-term mortality among tramadol users.
Marie Louise Tørring (2008)
10.1002/pds.4320
A 15‐year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom
Teng-Chou Chen (2018)
10.1002/acr.22360
Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis.
Elizabeth A. Wright (2014)
10.1186/s13018-016-0486-7
Polypharmacy and adverse outcomes after hip fracture surgery
Maria Härstedt (2016)
10.1016/j.joca.2016.01.135
Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review.
Savannah R. Smith (2016)
10.1016/j.joca.2015.10.006
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
J. N. Katz (2016)
10.1016/j.joca.2014.01.003
OARSI guidelines for the non-surgical management of knee osteoarthritis.
Timothy E. McAlindon (2014)
10.1016/j.nedt.2013.05.016
Medication fall risk in old hospitalized patients: a retrospective study.
Maria José Martins da Costa-Dias (2014)
10.1093/biomet/80.3.557
Checking the Cox model with cumulative sums of martingale-based residuals
D. Lin (1993)
10.1016/j.amjmed.2014.10.046
Tramadol for noncancer pain and the risk of hyponatremia.
Jean-Pascal Fournier (2015)
10.1136/bmj.b2538
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
Nicholas R Latimer (2009)
10.1001/jama.2016.1464
CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.
Deborah Dowell (2016)
10.1002/pds.1062
An application of propensity score matching using claims data.
John D Seeger (2005)
10.1001/jamainternmed.2014.6512
Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain.
Jean-Pascal Fournier (2015)
Osteoarthritis. Lancet. 2015;386(9991):376-387
S Glyn-Jones (2015)
10.1016/j.forsciint.2012.07.011
Comparison of fatal poisonings by prescription opioids.
Margareeta Häkkinen (2012)
10.1016/j.jemermed.2011.04.010
The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults
Nicole Seleno (2011)
10.1016/j.amjmed.2018.04.025
Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures.
Sameer Hassamal (2018)
10.1681/ASN.2017010098
Opioid Prescription, Morbidity, and Mortality in United States Dialysis Patients.
Paul L. Kimmel (2017)
10.5435/JAAOS-21-09-571
Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition.
David S. Jevsevar (2013)
10.1001/archinternmed.2010.391
The comparative safety of analgesics in older adults with arthritis.
Daniel H. Solomon (2010)
Imputation for Nonresponse in Surveys
Rubin DB.Multiple (1987)
10.1002/ACR.21596
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.
Marc C. Hochberg (2012)
10.3109/15563650.2013.872791
Drugs and other chemicals involved in fatal poisoning in England and Wales during 2000–2011
Simon James Handley (2014)
10.1186/s12916-015-0285-8
Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks
Carmelo Scarpignato (2015)
10.1155/2008/903784
Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial.
André D Beaulieu (2008)
10.1056/NEJMc1501822
Trends in opioid analgesic abuse and mortality in the United States.
Richard C Dart (2015)
10.2165/00003495-199600523-00007
Pharmacology and Clinical Experience with Tramadol in Osteoarthritis
Warren A. Katz (2012)
10.1136/bmj.k4209
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study
Blánaid Hicks (2018)
10.1093/aje/kwq198
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study.
Til Stürmer (2010)
10.1016/j.cgh.2017.10.022
Increasing Prescription of Opiates and Mortality in Patients With Inflammatory Bowel Diseases in England
Nicholas E Burr (2018)
10.1097/SLA.0b013e3181c1cfc9
Impaired Mobility, ASA Status and Administration of Tramadol are Risk Factors for Postoperative Delirium in Patients Aged 75 Years or More After Major Abdominal Surgery
Antoine Brouquet (2010)
10.1016/j.forsciint.2007.02.007
Fatal unintentional intoxications with tramadol during 1995-2005.
Micaela Tjäderborn (2007)
10.1111/j.1365-2796.2006.01667.x
Fracture risk associated with the use of morphine and opiates.
Peter Vestergaard (2006)
10.1016/j.jflm.2014.01.006
Tramadol deaths in Northern Ireland: a review of cases from 1996 to 2012.
Chandalar Randall (2014)
10.1056/NEJMsa1406143
Trends in opioid analgesic abuse and mortality in the United States.
Richard C Dart (2015)
10.1001/jama.2016.7789
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain.
W. A. Ray (2016)
10.1093/rheumatology/kew502
Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis
Alexis Ogdie (2017)



This paper is referenced by
10.1016/j.joca.2020.01.002
Osteoarthritis Year in Review 2019: Epidemiology and Therapy.
Margreet Kloppenburg (2020)
10.1016/j.joca.2019.05.020
Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study.
Jie Wei (2019)
10.1001/jama.2019.7224
Tramadol and Mortality in Patients With Osteoarthritis-Reply.
Guanghua Lei (2019)
10.1016/j.burns.2019.10.010
Impact of orally administered tramadol combined with self-selected music on adult outpatients with burns undergoing dressing change: A randomized controlled trial.
Xiu-Hang Zhang (2019)
10.1001/jama.2019.7216
Tramadol and Mortality in Patients With Osteoarthritis.
David T Felson (2019)
10.1017/cem.2020.50
Opioid prescription practices for patients discharged from the emergency department with acute musculoskeletal fractures.
Garrick Mok (2020)
10.1002/ejp.1496
Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open-label extension trials with a study duration ≥ 26 weeks.
Paul Bialas (2019)
10.1016/j.arth.2020.04.093
Preoperative Pain Management: Is Tramadol a Safe Alternative to Traditional Opioids Before Total Hip Arthroplasty?
Joshua A Bell (2020)
10.1016/j.arth.2020.01.055
Opioid Use After Total Knee Arthroplasty: Does Tramadol Have Lower Risk Than Traditional Opioids?
David E Demik (2020)
10.3390/jcm8081156
Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic
Alfredo Madrid-García (2019)
10.1016/j.medcli.2019.10.024
Use of opioids for chronic non-cancer pain.
Vicente Palop Larrea (2020)
10.1016/J.MONRHU.2019.07.001
Des recommandations sur la prise en charge de la coxarthrose: lecture critique
Magda Choueiri (2019)
10.1002/jbmr.3935
Association of Tramadol Use With Risk of Hip Fracture.
Jie Wei (2020)
10.1016/j.eclinm.2020.100321
The epidemiology of regular opioid use and its association with mortality: Prospective cohort study of 466 486 UK biobank participants
Gary John Macfarlane (2020)
10.1007/s40674-020-00140-3
Opioids and Cannabinoids for Osteoarthritis: Either, Both, or Neither
Ariane Barbacki (2020)
10.1136/bmjebm-2019-111236
Treating postoperative pain? Avoid tramadol, long-acting opioid analgesics and long-term use
Georgia C. Richards (2019)
10.1001/jama.2019.21558
Using Propensity Score Methods to Create Target Populations in Observational Clinical Research.
Laine E Thomas (2020)
10.1002/cpt.1910
Management of osteoarthritis during COVID‐19 pandemic
Enrico Ragni (2020)
10.1097/YIC.0000000000000319
Patterns of pharmacological treatment of patients with migraine, tension-type headache, and cluster headache in a large group of patients in Colombia, 2019
Jorge Enrique Machado-Alba (2020)
10.1016/j.joca.2019.10.001
Association of Tramadol with Risk of Myocardial Infarction Among Patients with Osteoarthritis.
Jie Wei (2019)
10.1111/ijcp.13416
Why are we still using opioids for osteoarthritis?
Kevin Yip (2019)
10.1097/CM9.0000000000000746
Toward wiping out osteoarthritis in China: research highlights
Zhi-zhong Ye (2020)
10.1186/s13063-020-04271-9
Usual care including home exercise with versus without spa therapy for chronic low back pain: protocol for the LOMBATHERM’ study, a multicentric randomised controlled trial
Romain J Forestier (2020)
10.1002/art.41142
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.
Sharon L. Kolasinski (2020)
10.1038/s41584-019-0360-1
Towards defining the safer use of opioids in rheumatology
Seoyoung C. Kim (2019)
10.1002/ejp.1519
Opioids for chronic low back pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least four weeks double-blind duration.
Frank Petzke (2019)
10.1136/bmjopen-2019-034363
Risk of opioid misuse in people with cancer and pain and related clinical considerations: a qualitative study of the perspectives of Australian general practitioners
Tim Luckett (2020)
10.1007/s00296-019-04332-6
Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis
Eugene J Kucharz (2019)
10.1007/s00482-020-00472-y
Empfehlungen der zweiten Aktualisierung der Leitlinie LONTS
Winfried Häuser (2020)
10.1111/bcp.13949
Translating the dose response into risk and benefit.
John B Warren (2019)
10.23970/ahrqepccer229
Opioid Treatments for Chronic Pain
Roger Chou (2020)
Efficacy and Safety of Naproxen vs Opioids for the Treatment of Musculoskeletal Pain
Stephen A. Brunton (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar